2-Butyl-4-methyl-1,3-dioxolane
Common Name: |
2-Butyl-4-methyl-1,3-dioxolane |
IUPAC Name: |
2-butyl-4-methyl-1,3-dioxolane |
Molecular Formula: |
C8H16O2 |
SMILES: |
CCCCC1OCC(O1)C |
Inchi: |
1S/C8H16O2/c1-3-4-5-8-9-6-7(2)10-8/h7-8H,3-6H2,1-2H3 |
Inchi Key: |
WTZJUXYVLRJTMQ-UHFFFAOYSA-N |
Cas No: |
74094-60-3 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
1 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
1 |
Name |
Value |
Molecular Weight (g/mol) |
144.21 |
Mass (g/mol) |
144.115 |
Molar Refractivity |
40.63 |
Net Charge |
|
HBD |
|
HBA |
2 |
Rt Bonds |
3 |
Rings |
1 |
TPSA |
18.46 |
Hetero Atoms |
2 |
Heavy Atoms |
10 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
|
Boiling Point (°C@760.00mm Hg) |
176.00 to 177.00 |
Vapor Pressure (mmHg@25.00 °C) |
2.325 |
Vapor Density (Air =1) |
|
Fraction Csp3 |
1.00 |
LogP |
1.938 |
iLOGP |
2.64 |
XLOGP3 |
2.09 |
WLOGP |
1.94 |
MLOGP |
1.31 |
ESOL Log S |
-1.85 |
ESOL Solubility (mg/ml) |
2.02 |
ESOL Solubility (mol/l) |
0.014 |
ESOL Class: esol_class |
Very soluble |
Ali Log S |
-2.11 |
Ali Solubility (mg/ml) |
1.13 |
Ali Solubility (mol/l) |
0.01 |
Ali Class |
Soluble |
Silicos-IT LogSw |
-1.70 |
Silicos-IT Solubility (mg/ml) |
2.91 |
Silicos-IT Solubility (mol/l) |
0.02 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
High |
BBB Permeable |
1 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-5.70 |
Bioavailability Score |
0.55 |
Caco2 |
1 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.693 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
0 |
Acute Oral Toxicity |
2.187 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
1 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |